A pivotal phase 2 clinical trial designed to help Celgene (CELG) and Bluebird Bio (BLUE) secure approval for the first CAR-T therapy targeting multiple myeloma will begin enrolling patients next week.

A listing for the clinical trial of the CAR-T therapy known as BB2121 was posted to the government’s ClinicalTrials.gov website on Tuesday, with a planned start date of Dec. 11. Celgene licensed BB2121 from Bluebird and is the sponsor of the study, which the company is calling KarMMA.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy